Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4451 The management of well-differentiated gastroenteropancreatic neuroendocrine tumours in a tertiary centre – The contribution of radionuclide therapy

Introduction: Neuroendocrine tumours represent a heterogenous group of tumours with different locations, whose management is necessary to identify specific parameters that determine the choice of optimal treatment.

Conference:

Presenting Author: Oana Stefania S

Authors: Oana Stefania S, Corin B, Victoria V, Sofia L,

Keywords: GEP-NET, well-differentiated, PRRT, Cromogranine A, Serotonin, RECIST 1.1,

#3826 Prognostic value of the neutrophil/lymphocyte ratio (NLR) in advanced, non resectable, progressive pancreatic and midgut NET after combine therapy using Lu-177 DOTATOC and CAPTEM

Introduction: Previous data suggest neutrophil/lymphocyte ratios (NLRs) could be used as prognostic factor in various solid tumors.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Pałucki J, Seklecka N,

Keywords: Neuroendocrine Tumor, Receptor, Somatostatin, CAPTEM radioligand therapy (RLT), Progression-Free Survival, Neutrophil lymphocyte ratio,

#3386 Peptide Radio Receptor Therapy induces immune activation in patients with neuroendocrine tumors and might sensitize to immunotherapy

Introduction: Peptide Radio Receptor Therapy (PRRT) is a standard treatment in patients with neuroendocrine tumors (NET), but treatment responses are limited and novel therapy combinations are needed. Since radiation induced cell death is considered immunogenic, patients might benefit from a combination of PRRT with immunotherapies, such as immune checkpoint inhibitors (ICI).

Conference:

Presenting Author: Büttner S

Authors: Büttner S, Detjen K, Galler M, Siefert J, Wiedenmann B,

Keywords: NET, PRRT, checkpoint inhibitors, immune response, PD1, flow cytometry,

#3284 Value of CgA and NSE as predictors of tumor response after combined PRRT and CAPTEM therapy in patients with progressive, advanced GEP-NET

Introduction: Combine PRRT and CAPTEM is a new approach in therapy of NET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ćwikła J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Nowicka G, Włodarczyk M, Nowicki M,

Keywords: CgA, NSE, neuroendocrine tumor, PRRT and CAPTEM,

#3267 High efficacy of combined PRRT and CAPTEM therapy based on objective response rate (RECIST) in patients with pancreatic and midgut neuroendocrine tumors (NET)

Introduction: PRRT and chemotherapy might be an option.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Nowicki , Zrajkowska A, Pałucki , Nowicka G,

Keywords: neuroendocrine tumor, pancreatic, midgut, DCR, ORR,